AbCellera Biologics (ABCL) Debt to Equity (2020 - 2025)
Historic Debt to Equity for AbCellera Biologics (ABCL) over the last 6 years, with Q1 2025 value amounting to $0.01.
- AbCellera Biologics' Debt to Equity fell 8116.35% to $0.01 in Q1 2025 from the same period last year, while for Mar 2025 it was $0.01, marking a year-over-year decrease of 8116.35%. This contributed to the annual value of $0.01 for FY2024, which is 8251.82% down from last year.
- According to the latest figures from Q1 2025, AbCellera Biologics' Debt to Equity is $0.01, which was down 8116.35% from $0.01 recorded in Q4 2024.
- In the past 5 years, AbCellera Biologics' Debt to Equity ranged from a high of $0.05 in Q2 2023 and a low of $0.01 during Q4 2024
- Over the past 5 years, AbCellera Biologics' median Debt to Equity value was $0.02 (recorded in 2022), while the average stood at $0.03.
- As far as peak fluctuations go, AbCellera Biologics' Debt to Equity skyrocketed by 13615.63% in 2022, and later tumbled by 8251.82% in 2024.
- AbCellera Biologics' Debt to Equity (Quarter) stood at $0.02 in 2021, then skyrocketed by 60.33% to $0.04 in 2022, then grew by 22.19% to $0.04 in 2023, then crashed by 82.52% to $0.01 in 2024, then rose by 11.97% to $0.01 in 2025.
- Its Debt to Equity stands at $0.01 for Q1 2025, versus $0.01 for Q4 2024 and $0.02 for Q3 2024.